Clinical Outcome Assessments: Establishing and Interpreting Meaningful Within-Patient Change
The Center for Strategic and International Studies • Washington, DC
April 4, 2017

Participant List

Heather Adams
Associate Professor of Neurology and Pediatrics, University of Rochester Medical Center

Julie Beitz
Director, Office of Drug Evaluation III, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Vance Berger
Mathematical Statistician, National Cancer Institute

Steven Blum
Director, Patient Reported Outcomes, GlaxoSmithKline

Michelle Campbell
COA Reviewer and COA Qualification Scientific Coordinator, Clinical Outcomes Assessments Staff, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Robyn Carson
Director, Health Economics & Outcomes Research, Allergan

Wen-Hung Chen
Reviewer, Clinical Outcome Assessment Staff, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Badrul Chowdhury
Director, Division of Pulmonary, Allergy, and Rheumatology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

David Clissold
Director, Hyman, Phelps, & McNamara

Karon Cook
Research Professor, Department of Medical Social Sciences, Northwestern Feinberg School of Medicine

Stephen Joel Coons
Executive Director, Patient-Reported Outcome (PRO) Consortium, Critical Path Institute (C-Path)

Donna Cryer
President & CEO, Global Liver Institute

Gregory Daniel
Deputy Director, Duke-Margolis Center for Health Policy, Duke University

Selena Daniels
Team Leader – Clinical Outcome Assessments, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Linda Deal
Senior Director and Head of Patient-Centered Outcomes Assessment, Pfizer
Esi Morgan DeWitt  
Associate Professor of Pediatrics, University of Cincinnati College of Medicine, and Co-Clinical Director, Division of Rheumatology, Cincinnati Children’s Hospital

Dana DiBenedetti  
Executive Director, Patient-Centered Outcomes Assessment, RTI Health Solutions

Chris Edgar  
Senior Outcomes Research Scientist, Patient-Centered Outcomes Research, Roche

Meredith Freed  
Senior Research Assistant, Duke-Margolis Center for Health Policy, Duke University

Denise Globe  
Vice President and Head US Oncology Health Outcomes Research, Novartis

Chad Gwaltney  
Principal Consultant, Gwaltney Consulting

Katarina Halling  
Global Head, Patient Science, AstraZeneca

Martin Ho  
Associate Director for Quantitative Innovation, Center for Devices and Radiological Health, U.S. Food and Drug Administration

Charlie Iaconangelo  
Psychometrician, Endpoint Outcomes

Hylton Joffe  
Director, Division of Bone, Reproductive and Urologic Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Laura Lee Johnson  
Deputy Division Director, Division of Biometrics III, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lisa Kammerman  
Senior Statistical Science Director, AstraZeneca

Richard Keefe  
Professor of Psychiatry, Psychology & Neuroscience, Duke University Medical Center

Paul Kluetz  
Associate Director of Patient Outcomes (Acting), Oncology Center of Excellence, U.S. Food and Drug Administration

Scott Komo  
Senior Statistical Reviewer, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Lisa LaVange  
Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Mary Kay Margolis  
Senior Program Officer, Evaluation and Analysis, Patient-Centered Outcomes Research Institute (PCORI)

Patrick Marquis  
Chief Executive Officer, Modus Outcomes

Mark McClellan  
Director, Duke-Margolis Center for Health Policy, Duke University
Sandra Mitchell  
Research Scientist and Program Director, Outcomes Research Branch, Healthcare Delivery Research Program, National Cancer Institute  

Theresa Mullin  
Director, Office of Strategic Programs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Elektra Papadopoulos  
Associate Director, Clinical Outcomes Assessment Staff, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Nikunj Patel  
Reviewer – Clinical Outcome Assessments, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Eleanor Perfetto  
Senior Vice President, Strategic Initiatives, National Health Council  

Thomas Permutt  
Director, Division of Biometrics II, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Dennis Revicki  
Senior Vice President and Executive Director Center of Excellence for Outcomes Research, Evidera  

Elizabeth Richardson  
Managing Associate, Duke-Margolis Center for Health Policy, Duke University  

Dragos Roman  
Associate Director, Division of Gastroenterology & Inborn Errors Products, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Bruce Schneider  
Clinical Team Leader, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration  

Daniel Serrano  
Director of Psychometrics and Statistics, Endpoint Outcomes  

Cynthia Sitcov  
Co-Owner, Sitcov Director  

Peter Stein  
Deputy Director, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Norman Stockbriedge  
Director, Office of Drug Evaluation I, Division of Cardiovascular and Renal Products, U.S. Food and Drug Administration  

David Thissen  
Professor, Department of Psychology, University of North Carolina at Chapel Hill  

Ellis Unger  
Director, Office of New Drugs, Office of Drug Evaluation I, Center for Drug Evaluation and Research, U.S. Food and Drug Administration  

Pujita Vaidya  
Operations Research Analyst, Office of Strategic Programs, Center for Drug
Evaluation and Research, U.S. Food and Drug Administration

Marc Walton
Senior Scientific Director, Janssen Research and Development

Albert Wu
Professor of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health

Kathy Wyrwich
Senior Research Advisor, Patient-Focused Outcomes Center of Expertise, Eli Lilly and Company